ArticleJournal of experimental & clinical cancer research : CR2010
Overexpression of candidate tumor suppressor ECRG4 inhibits glioma proliferation and invasion.
Article in Journal of experimental & clinical cancer research : CR, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Identifying novel glioma associated pathways based on systems biology level meta-analysis.BMC systems biology · 2013Pooled it
- Mechanisms and therapeutic potential of glycyrrhizic acid: Insights into key signaling pathways and disease modulation (Review).Molecular medicine reports · 2026Review
- Complex and pleiotropic signaling pathways regulated by the secreted protein augurin.Cell communication and signaling : CCS · 2023Review
- Microglial Homeostasis Requires Balanced CSF-1/CSF-2 Receptor Signaling.Cell reports · 2020Article
- Potential functions of esophageal cancer-related gene-4 in the cardiovascular system.Frontiers of medicine · 2019Review
- ECRG4: a new potential target in precision medicine.Frontiers of medicine · 2019Review
- ECRG4 acts as a tumor suppressor gene frequently hypermethylated in human breast cancer.Bioscience reports · 2019Article
- Serum exosomes contain ECRG4 mRNA that suppresses tumor growth via inhibition of genes involved in inflammation, cell proliferation, and angiogenesis.Cancer gene therapy · 2018Article
- Ecrg4 peptide is the ligand of multiple scavenger receptors.Scientific reports · 2018Article
- Downregulation and DNA methylation of ECRG4 in gastric cancer.OncoTargets and therapy · 2018Article
- Downregulation of esophageal cancer-related gene 4 promotes proliferation and migration of hepatocellular carcinoma.Oncology letters · 2017Article
- A short synthetic peptide fragment of human C2ORF40 has therapeutic potential in breast cancer.Oncotarget · 2017Article
- Association of ECRG4 with PLK1, CDK4, PLOD1 and PLOD2 in esophageal squamous cell carcinoma.American journal of translational research · 2017Article
- Soluble purified recombinant C2ORF40 protein inhibits tumor cell growthOncology letters · 2016Article
- ECRG4 as a novel tumor suppressor gene inhibits colorectal cancer cell growth in vitro and in vivo.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Down-regulated ECRG4 expression in breast cancer and its correlation with tumor progression and poor prognosis--A short Report.Cellular oncology (Dordrecht, Netherlands) · 2016Article
- Downregulated ECRG4 is associated with poor prognosis in renal cell cancer and is regulated by promoter DNA methylation.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- A preliminary study of the effect of ECRG4 overexpression on the proliferation and apoptosis of human laryngeal cancer cells and the underlying mechanisms.Molecular medicine reports · 2015Article
- Soluble purified recombinant C2ORF40 protein inhibits esophageal cancer cell proliferation by inducing cell cycle GOncology letters · 2015Article
- ECRG4 acts as a tumor suppressor and as a determinant of chemotherapy resistance in human nasopharyngeal carcinoma.Cellular oncology (Dordrecht, Netherlands) · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundECRG4 has been shown to be a candidate tumor suppressor in several tumors, but its role in glioma remains poorly understood. In this study, we examined the mRNA expression of ECRG4 and investigated its biological role in glioma cells.
methodsReal-time PCR was used to examine expression of ECRG4 in gliomas and their matched brain tissues. The effect of ECRG4 expression on cell proliferation, invasion, and migration was investigated in human U251 glioma cells. Finally, the regulation of transcription factor NF-kB by ECRG4 was evaluated by western blotting.
resultsOf the 10 paired samples analyzed, 9 glioma tissues displayed the decreased expression of ECRG4 compared to matched normal brain tissues. Cells transfected with ECRG4 showed significantly decreased cell proliferation as evaluated by MTT and colony formation assays. Furthermore, overexpression inhibited cell migration and invasion in transwell and Boyden chamber experiments and retarded the cell cycle progression from G1 to S phase by FACSCaliber cytometry. Protein levels of nuclear transcription factor NF-kB, which is involved in cell proliferation, inversely correlated with ECRG4 expression.
conclusionOur data suggest that ECRG4 serves as a tumor suppressor in glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.